Spartan Capital Securities, LLC’s Post

Spartan Capital Securities, LLC is excited to welcome Chromocell Therapeutics Corporation (NYSE: CHRO) as a presenting company at the Spartan Capital Investor Conference 2024, taking place on November 4th at The Pierre Hotel in New York City.   Chromocell is a pioneer in the development of non-opioid pain treatment therapeutics with a focus on modulating NaV1.7 receptors responsible for sensing and transmitting pain in the peripheral nervous system. The Company’s programs targeting the treatment of chronic neuropathic and acute and chronic eye pain are based on its patented core molecules. Chromocell Therapeutics Corp.'s leadership team includes Frank Knuettel II, Eric Lang, Simon P. Chandler, Richard Malamut, and Anke Hoppe. Conference attendees will be uniquely able to engage directly with Chromocell Therapeutics Corp. executives, gaining valuable insights into the company’s development and commercializing new therapeutics to alleviate pain.   This one-day event brings together public company executives, institutional investors, and capital market leaders. With over 30 presenting companies, it promises an unparalleled networking experience.   To secure your place at this premier event, visit: https://lnkd.in/enQCABXZ   #SpartanCapital #B2iDigital #InvestorConference #CapitalMarkets #InstitutionalInvestors #SpartanCapitalInvestorConference2024 #ChromocellTherapeutics #CHRO

We're honored to welcome Chromocell Therapeutics Corporation (NYSE: $CHRO) to participate in the upcoming B2i Digital Featured Conference: Spartan Capital Securities, LLC Investor Conference 2024. The event is scheduled for November 4th at The Pierre Hotel in New York City. Chromocell is a pioneer in the development of non-opioid pain treatment therapeutics with a focus on modulating NaV1.7 receptors responsible for sensing and transmitting pain in the peripheral nervous system. The Company’s programs targeting the treatment of chronic neuropathic and acute and chronic eye pain are based on its patented core molecules. Chromocell Therapeutics Corp.'s leadership team includes Frank Knuettel II, Eric Lang, Simon P. Chandler, Richard Malamut, and Anke Hoppe. Conference attendees will be uniquely able to engage directly with Chromocell Therapeutics Corp. executives, gaining valuable insights into the company’s development and commercializing new therapeutics to alleviate pain. The Spartan Capital Investor Conference brings together an impressive array of public company executives, institutional investors, and thought leaders in the U.S. capital markets. With over 30 companies slated to present, the event promises unparalleled networking opportunities. For those interested in attending this exclusive event, please submit a request to participate at https://lnkd.in/e6ZQhZyA Kindly note that attendance is limited and subject to approval. Thank you to our hosts at Spartan Capital who made this event possible: John D. Lowry, Kim Monchik, Joe Giamichael, Stephen Faucetta, Julia Voss, William Birney, Donald Powell, Louis Valdez, Abdiell (AJ) Suero, Blake Weltmann, Ralph Metz and many others. Spartan Capital Securities, LLC is a full-service, integrated financial services firm trusted by high-net-worth individuals and institutions for sound investment guidance. We focus on understanding our clients' objectives and executing strategies to meet their financial goals. #SpartanCapital #B2iDigital #InvestorConference #CapitalMarkets #InstitutionalInvestors #SpartanCapitalInvestorConference2024 #ChromocellTherapeutics #CHRO

Alentis Therapeutics Secures $181M to Advance Targeted Therapies for Solid Tumors Alentis Therapeutics, a leading biopharmaceutical company developing targeted treatments for cancer and fibrotic diseases, has secured $181.4 million in Series D funding round to develop targeted therapies for solid tumors. The financing round was spearheaded by OrbiMed, Novo Holdings, and JEITO, with significant contributions from new investors Longitude Capital, Frazier Life Sciences, Catalio Capital Management, Avego, and Piper Heartland Healthcare Capital. Existing investors RA Capital Management, MORNINGSIDE VENTURES LIMITED, Bpifrance, and BB Pureos, along with key institutional investors, participated in the round. Read more: https://lnkd.in/gAcbpysY Roberto Iacone, Dr. Luigi Manenti, Jonathan Freve, Markus Meyer, Alberto Toso #HealthcareNews #HealthcareInnovation #HealthcareTechnology #DrugDiscovery #FundingNews

𝗦𝗶𝘁𝗲𝗢𝗻𝗲 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀, 𝗮 𝗽𝗮𝗶𝗻 𝗯𝗶𝗼𝘁𝗲𝗰𝗵 𝘁𝗵𝗮𝘁'𝘀 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝗲𝗱 𝘄𝗶𝘁𝗵 𝗩𝗲𝗿𝘁𝗲𝘅, 𝗻𝗮𝗯𝘀 $𝟭𝟬𝟬𝗠 About eight years after its Series B, a small biotech working on non-opioid treatments has raised its Series C to gather clinical proof of concept …John Mulcahy, Ph.D. SiteOne Therapeutics, Inc. https://lnkd.in/dmN67KQG

Revolutionary #condensate science with broad applicability across therapeutic areas, an #AI-powered state-of-the-art discovery platform, unrivaled expertise, and a culture that nourishes growth and innovation are only a few reasons why Dewpoint Therapeutics is One to Watch.  🧾 Read more in this article published in The Pharma Letter: https://lnkd.in/eyWr54yJ  

Day 1: Working on #oligonucleotide-based therapies? Connect with our WuXi TIDES team at the 9th OPT Congress in Boston from March 13-14. On March 13 at 12:45 pm EST, Yvonne Angell, Ph.D., our Executive Director and Head of TIDES discovery project management, will outline the technical challenges encountered in the discovery phase of oligonucleotide therapeutics. Through two case studies, we’ll detail our strategies for advancing programs from discovery to development, addressing technical obstacles and optimizing our approach. This presentation will offer practical insights for navigating the complexities of oligonucleotide therapy development.   Schedule a meeting with our team: WuXi_TIDES@wuxiapptec.com Learn more: https://lnkd.in/g6AmChYd #WuXiTIDES #peptides #oligonucleotides #CRDMO

Alphina Therapeutics continues to add to its senior leadership team as it works to discover and develop novel treatments for a range of solid #tumor indications. The company has appointed Marc Damelin as Chief Scientific Officer, and will lean on his deep #oncology drug discovery and development expertise to guide the advancement of its best-in-class #NAMPT inhibitor program toward the clinic. Dr. Damelin has served in key scientific leadership roles for 17 years, including tenures with Pfizer and Mersana Therapeutics. During that time he has made important contributions to the discovery of multiple platform technologies and clinical compounds that resulted in several high-value partnerships. Canaan's Colleen Feriod Cuffaro sits on Alphina's board of directors. Read the company’s press release on Dr. Damelin's appointment here: https://lnkd.in/eiCz-BuD

SiteOne Therapeutics, a Bay Area pain biotech 14 years in the making, has raised a $100 million Series C eight years after its Series B. The long gap is a sign of the difficulties startups have faced in attempting to develop new, non-opioid pain treatments. Its partner Vertex, though, opened the doors with its experimental Nav1.8 medicine, which is due for an FDA approval decision at the end of January. SiteOne's lead internal candidate, in Phase 1, is also a Nav1.8 small molecule. More from my interview with SiteOne co-founder and CEO John Mulcahy: #painbiotech #pain #nonopioid #biotechvc #biotechfunding #nav18 #sodiumionchannel #biotechmegaround #acutepain #chronicpain #novoholdings #orbimed #vertex #latigobiotherapeutics

Achieving Next-Generation mRNA-LNP Therapeutics Delivery https://lnkd.in/e_H8yJEJ Three LNP experts (Dr. Kate Zhang, Professor Ben Muir, and Dr. Sumit Luthra) parse out the current opportunities and unknowns facing the development of next-generation LNPs.

EQT Life Sciences Leads Series B Extension in Noema Pharma, Raising Total Series B Financing to CHF130 Million. Noema Pharma is a clinical-stage biotech company developing a pipeline of first-in-disease therapeutics that address central nervous system (CNS) disorders. The investment builds on EQT Life Sciences’ previous successful partnership with neurology-focused repeat entrepreneur and Noema Pharma CEO Ilise Lombardo , MD. Learn more about the investment here: https://lnkd.in/ewSTE5J6